XLRN News and Press, Acceleron Pharma Inc. From 06/10/19

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis, PhD, is retiring from his position on its Board of Director...

The FDA accepts for review Celgene's (NASDAQ: CELG ) marketing application seeking approval for luspatercept for beta-thalassemia and myelodysplastic syndromes. More news on: Celgene Corporation, Acceleron Pharma Inc., Healthcare stocks news, Read more ...

U.S. Food and Drug Administration grants priority review for beta-thalassemia indication and sets target action date of December 4, 2019 U.S. Food and Drug Administration sets target action date of April 4, 2020 for myelodysplastic syndromes indication Luspatercept EU Marketing Au...

Today, we take an in-depth look at a mid-cap development play that filed an important application to the FDA just under two months ago. Company Overview: Acceleron Pharma Inc. ( XLRN ) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company focused on the developme...

Cyclacel Pharmaceuticals (NASDAQ: CYCC ) initiated with Buy rating and $8 (1173% upside) price target at Roth Capital Partners. More news on: Cyclacel Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Fate Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the UBS Global Healthcare Conference on Monda...

Acceleron Pharma, Inc. (XLRN) Q1 2019 Earnings Conference Call May 9, 2019, 5:00 pm ET Company Participants Todd James - VP, IR & Corporate Communications Habib Dable - CEO Kevin McLaughlin - CFO John Quisel - CBO Sujay Kango - CCO Conference Call Participants Carte...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2019 Q1 earnings Read more ...

Acceleron Pharma (NASDAQ: XLRN ): Q1 GAAP EPS of -$0.74 misses by $0.10 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– Luspatercept Biologics License Application (BLA) and Marketing Authorization Application (MAA) submitted in April 2019 – – Part 2 results from the ACE-083 Phase 2 trials in facioscapulohumeral muscular dystrophy (FSHD) expected in the second half of 2019 and Char...